Asahi Techno Research Exhibits at CPHI Japan 2026, Proposing One-Stop Support for Nitrosamine Analysis and Synthesis

May 18, 2026 - Asahi Techno Research Co., Ltd. (Representative Director: Osamu Banjo, Headquarters: Otake, Hiroshima), a group of experts in analysis and experimentation for environmental surveys and quality assurance, guided by the corporate philosophy 'to constantly seek new technologies and knowledge, serve customers with sincerity, and never stop moving forward,' exhibited at the International Pharmaceutical Development Expo 'CPHI Japan 2026,' held at Tokyo Big Sight from April 21 (Tue) to 23 (Thu), 2026. In recent years, against the backdrop of strengthening regulations on nitrosamine impurities, which are suspected to be strongly carcinogenic, the need for high-sensitivity and high-precision analysis in pharmaceutical companies and CDMOs (Contract Development and Manufacturing Organizations) has been rapidly increasing. At this exhibition, in collaboration with our group company, Watanabe Chemical Industries, Ltd., we widely promoted our group's strength in providing one-stop, integrated support 'from synthesis of standards to analysis.' During the event, visitors to our booth showed high interest in our 'integrated support from synthesis to analysis,' 'domestic quality control system,' and 'analytical support.' Background of Exhibition CPHI is an international exhibition where companies involved in the entire pharmaceutical supply chain (raw materials, manufacturing, analysis, quality) gather. The 'quality control support' and 'impurity analysis' services we provide have a high affinity with the exhibition's themes of 'stable supply,' 'manufacturing efficiency,' and 'technological innovation,' making it the most effective venue to communicate our value proposition to the pharmaceutical industry. Currently, the following issues are becoming apparent in the pharmaceutical industry: ● Increased analytical burden due to strengthened regulations on nitrosamine and other impurities ● Increasing demands for high-sensitivity and high-precision analysis ● Strengthening of quality control systems to maintain a stable supply ● Increased demand for speed in analysis, evaluation, and countermeasures. Exhibition Content At this exhibition, we focused on the following three services and solutions. We perform simultaneous analysis of nitrosamines using a Liquid Chromatograph Mass Spectrometer (LC-MS/MS) capable of high-sensitivity and high-precision measurements. Service Name / Overview: Nitrosamine Analysis Service: Responds to the impurity analysis needs of pharmaceutical companies and CDMOs by leveraging high-sensitivity analysis technology and the ability to apply analytical methods to a diverse range of compounds. Prompt response is also one of our strengths. NDSRI Support (Nitrosamine Drug Substance Related Impurities): Specialized analysis and evaluation support for nitrosamine-related impurities derived from drug substances (NDSRIs). This can also be used for data acquisition for new drug applications. Synthesis and Supply of Related Impurities/Standards (Watanabe Chemical Industries): Provides comprehensive solutions that don't just end with analysis, offering integrated support from structural identification and synthesis of causative substances to the supply of standards. Liquid Chromatograph Mass Spectrometer (LC-MS/MS). Features of Our Technology Our group's greatest strength lies in our 'integrated support from synthesis to analysis.' We don't just present analysis results; our group provides the following in a seamless manner: ● Detection and quantification of trace nitrosamines using high-sensitivity analysis technology ● Ability to build analytical methods for a diverse range of compounds ● Structural identification and synthesis of causative substances ● Custom support tailored to individual challenges. This allows us to provide one-stop support from early detection of quality risks to the planning and execution of countermeasures. Furthermore, our group has a proven track record of contracted analysis for nitrosamines and related impurities in pharmaceutical formulations and commercial drugs. For new projects, we can efficiently develop testing methods by leveraging our accumulated analytical experience and knowledge. In addition to the analysis of nitrosamines and related impurities, we also support the analysis of elemental impurities in drug substances, performing high-sensitivity metal analysis using ICP/MS. In recent years, the importance of comprehensive quality risk management, including not only nitrosamines but also elemental impurities, has been growing in the pharmaceutical field. Our group utilizes a wide range of analytical technologies to provide comprehensive support for quality assurance and regulatory compliance in pharmaceutical companies. Pharmaceutical manufacturing sites are globally dispersed, and the manufacturing and analysis of drug substances and intermediates overseas have become common. On the other hand, from the perspective of quality assurance and stable supply, there is a growing need to restructure manufacturing and quality control systems within Japan. Our group has actually received inquiries such as, 'We want to transfer synthesis and analysis conducted overseas to Japan. We are looking for a partner in Japan who can provide an equivalent level of support.' Our group has both analysis and synthesis functions within Japan and has a system in place to support a smooth domestic transfer by providing integrated support from the synthesis, analysis, and evaluation of nitrosamine-related substances. About Asahi Techno Research Representative: Osamu Banjo, Representative Director. Established: May 1989. Location: 2-10-54 Harumi, Otake-shi, Hiroshima. Corporate URL: https://agi-atr.com/ Business: Environmental measurement and analysis (water quality, soil, waste, asbestos), quality testing of water for pharmaceutical manufacturing, quality investigation (RoHS/ELV, material analysis), technology development.